Meeting date: 5th July 2021
Prescribing information for MAYZENT▼ (siponimod) and adverse event reporting details can be found here.
Prescribing information for GILENYA▼ (fingolimod) and adverse event reporting details can be found here.
This webinar took place originally on the 5th of July. On the 12th of July, KESIMPTA (ofatumumab) was accepted by the SMC.1
Speakers: Dr David Paling, Consultant Neurologist, Sheffield Teaching Hospitals; Joela Mathews, Lead Neuroscience Pharmacist for Barts Health NHS Trust.
In this webinar, consultant neurologist Dr David Paling and specialist pharmacist Joela Mathews discuss the treatment of MS patients outside of the hospital setting. Considering the latest data, they explore how integrating KESIMPTA (ofatumumab) into local patient pathways could benefit both patients and healthcare services.
This meeting was organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Service impact case study
Watch Joela Mathews explore the variations in care and capacity issues in MS treatment, and how home infusion can improve the patient pathway and reduce healthcare costs.
Service impact example
See Joela Mathews discuss the patient and healthcare pathways in MS, and how KESIMPTA can help generate efficiencies by moving care closer to home.
KESIMPTA demonstration pen injection
Watch Dr David Paling demonstrate how easy it is to use the KESIMPTA Sensoready® injection pen, and how it can benefit patients.
MS, multiple sclerosis; SMC, Scottish medicines consortium.
Reference
- Scottish Medicines Consortium (2021). Advice following a full submission: ofatumumab (Kesimpta®) is accepted for restricted use within NHSScotland. Available at: https://www.scottishmedicines.org.uk/medicines-advice/ofatumumab-kesimpt... [Accessed July 2021].